Jazz Pharmaceuticals & Pharma Mar v. RK Pharma: Zepzelca Patent Action Voluntarily Dismissed
Jazz Pharmaceuticals Ireland Limited and Pharma Mar, SA filed a patent infringement action in Delaware against RK Pharma and three co-defendants over US7763615B2, the patent covering Zepzelca® (lurbinectedin) for injection. The case was voluntarily dismissed just 63 days after filing, with the public record silent on whether dismissal was with or without prejudice.
Lurbinectedin IP dispute ends at 63 days — terms undisclosed
On 12 September 2024, Jazz Pharmaceuticals Ireland Limited and Pharma Mar, SA filed a patent infringement action in the U.S. District Court for the District of Delaware before Judge Gregory B. Williams. The defendants named were RK Pharma, Inc., ARCHIS PHARMA LLC, Apicore US, LLC, and Vgyaan Pharmaceuticals, LLC — a cluster of generic pharmaceutical entities. The asserted patent, US7763615B2, underpins Zepzelca® (lurbinectedin) 4 mg/vial for intravenous injection, an oncology product approved for relapsed or refractory small cell lung cancer.
The case was terminated on 14 November 2024 — just 63 days after filing — following a voluntary dismissal notice filed by both plaintiffs. The court entered a corresponding order terminating the civil case. The basis of termination is recorded solely as ‘Voluntary dismissal,’ with no public indication of whether the dismissal was entered with or without prejudice. No defendant law firm, no defendant agents, and no substantive motions appear on the public docket, which is consistent with a very early resolution.
A 63-day lifespan is unusually short even by the standards of early-stage pharmaceutical patent disputes, suggesting the plaintiffs may have reached a private agreement with some or all defendants, identified a procedural defect, or chosen to refile strategically — though none of these can be confirmed from the public record. What drove the voluntary dismissal, whether any licensing terms were reached, and whether refiling against any of the four defendants remains a possibility cannot be determined from available information.
Filing to Voluntary dismissal in 63 days
63 days — resolved well below the typical multi-year ANDA patent litigation timeline
Voluntarily dismissed: what the record does and does not tell us
Voluntary dismissal — Rule 41 without stated prejudice qualifier
A voluntary dismissal under Federal Rule of Civil Procedure 41 allows a plaintiff to withdraw its case. Critically, the legal effect differs sharply depending on whether dismissal is ‘with’ or ‘without’ prejudice. With prejudice bars refiling permanently; without prejudice preserves the right to refile. The public record in this case identifies only ‘Voluntary dismissal’ — the prejudice qualifier is not specified, leaving the operative legal effect unclear from publicly available documents.
Rule 41 — prejudice qualifier unspecifiedWith or without prejudice? The record is silent
This distinction is commercially material. A dismissal without prejudice means Jazz Pharmaceuticals and Pharma Mar could refile against any or all four defendants if circumstances change — for example, if a defendant proceeds with an ANDA or NDA approval. A dismissal with prejudice would extinguish that right permanently. The public docket does not resolve this question, and the court’s termination order reflects only the voluntary dismissal notice without elaborating on prejudice terms.
Refiling risk: unresolvedFour generic entities exit without a merits ruling
RK Pharma, ARCHIS PHARMA, Apicore US, and Vgyaan Pharmaceuticals each avoided any substantive court ruling on patent validity or infringement. No defendant counsel appeared on the docket, which is consistent with resolution before formal engagement. However, the absence of a merits ruling means US7763615B2 was neither invalidated nor found not infringed — the patent’s enforceability against these defendants remains legally intact unless a private agreement dictates otherwise.
No invalidity or non-infringement findingZepzelca® exclusivity position unchanged — early withdrawal is cautiously positive for plaintiffs
Because the case resolved before any substantive ruling, US7763615B2 emerges without adverse judicial findings. For Jazz and Pharma Mar, this preserves the patent’s enforceability against future generic challengers. For the broader lurbinectedin market, the rapid closure suggests either a private arrangement with the named defendants or a strategic pivot — neither of which reduces the deterrent effect of the patent for other potential generics entering the market.
Patent intact — enforceability preservedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Jazz Pharmaceuticals Ireland Limited | Individual | Pharmaceutical patent holders — Zepzelca® (lurbinectedin) co-developers and co-owners of US7763615B2Search in Eureka ↗ |
| Co-Plaintiff | Pharma Mar, SA | Company | Search in Eureka ↗ |
| Defendant | Rk Pharma, Inc. | Company | Generic pharma entities: RK Pharma, ARCHIS PHARMA, Apicore US, and Vgyaan PharmaceuticalsSearch in Eureka ↗ |
| Co-Defendant | ARCHIS PHARMA LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Apicore US, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Vgyaan Pharmaceuticals, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Daniel A. O’Brien | Attorney | Counsel for Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Plaintiff law firm | Venable LLP | Law Firm | Representing Jazz Pharmaceuticals Ireland LimitedSearch in Eureka ↗ |
| Presiding judge | Judge Gregory B. Williams | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The court’s termination order reflects a ministerial acknowledgment of the plaintiffs’ voluntary dismissal notice — it carries no adjudicative weight on infringement, validity, or claim scope. The phrase ‘Civil Case Terminated’ confirms only procedural closure. Because no substantive motions were decided, this order creates no estoppel, collateral estoppel, or res judicata effect on the merits of US7763615B2 against any of the four named defendants or any future respondent.
US7763615B2 — Lurbinectedin compound and oncology formulation
US7763615B2 (application number US10/485,536) is the core compound patent asserted to protect Zepzelca® (lurbinectedin) 4 mg/vial for intravenous use. Lurbinectedin is a synthetic alkaloid that binds covalently to the minor groove of DNA and inhibits transcription, with approved indication for relapsed or refractory small cell lung cancer in adults. The B2 designation confirms the patent has undergone post-grant reexamination or correction proceedings, which may affect claim scope — a material consideration for any freedom-to-operate assessment.
US7763615B2 represents a significant exclusivity asset jointly controlled by Pharma Mar, SA (originator) and Jazz Pharmaceuticals (U.S. commercialisation partner). Given lurbinectedin’s orphan drug and oncology designation, the patent operates in a competitive environment where generic entry typically triggers multi-front litigation. The four-defendant action in this case suggests active monitoring of the API and formulation supply chain, consistent with a coordinated IP enforcement programme protecting a high-value oncology franchise.
Should you run an FTO against US7763615B2 before developing lurbinectedin generics?
Any pharmaceutical company, API manufacturer, or CDMO engaged in lurbinectedin synthesis, formulation, or testing for potential ANDA or 505(b)(2) submission should treat US7763615B2 as a primary clearance obligation. The voluntary dismissal in this case does not represent a safe harbour — the patent remains fully in force and Jazz Pharmaceuticals and Pharma Mar have demonstrated willingness to name API suppliers and formulators as co-defendants, not just finished-product manufacturers.
PatSnap Eureka’s FTO Search Agent can map the full claim landscape of US7763615B2, identify continuation and divisional filings by Pharma Mar and Jazz across jurisdictions, and flag prosecution history estoppel arguments that may define workaround freedom. For R&D teams modelling generic entry timelines for lurbinectedin, Eureka’s portfolio analytics provide visibility into expiry dates, reexamination history, and comparable enforcement actions across the oncology small-molecule space.
Run a freedom-to-operate analysis on US7763615B2 to assess your product’s exposure
Run FTO in Eureka →Similar oncology patent infringement cases in Delaware District Court
Explore comparable small-molecule oncology patent infringement actions filed in the District of Delaware involving voluntary dismissals, ANDA triggers, and multi-defendant enforcement strategies.
What this case signals for the lurbinectedin and oncology IP landscape
A 63-day voluntary dismissal in a four-defendant pharmaceutical patent case warrants scrutiny from generic pharma entrants and oncology IP teams.
Voluntary dismissal without merits leaves US7763615B2 unchallenged
No court assessed validity or infringement of the lurbinectedin patent. Generic developers considering ANDA or 505(b)(2) pathways for lurbinectedin cannot rely on this case as precedent — the patent stands fully enforced. Any entity contemplating a generic entry should treat US7763615B2 as an active enforcement risk requiring independent FTO analysis.
Four-defendant structure suggests broad enforcement posture by Jazz and Pharma Mar
Naming four generic entities simultaneously — RK Pharma, ARCHIS PHARMA, Apicore US, and Vgyaan Pharmaceuticals — signals that plaintiffs are monitoring the lurbinectedin supply chain closely, including API suppliers and formulators. Companies involved in lurbinectedin API manufacture or formulation development should assess their exposure to US7763615B2 regardless of this case’s early closure.
Limited v Rk — key questions answered
The case was voluntarily dismissed on 14 November 2024, 63 days after filing. The court entered an order terminating the civil case following a voluntary dismissal notice filed by plaintiffs Jazz Pharmaceuticals Ireland Limited and Pharma Mar, SA. The public record does not specify whether the dismissal was with or without prejudice.
The asserted patent is US7763615B2 (application no. US10/485,536), which covers Zepzelca® (lurbinectedin) for injection, 4 mg/vial for intravenous use. Lurbinectedin is a synthetic DNA minor-groove binder approved for relapsed or refractory small cell lung cancer.
No. A voluntary dismissal under Rule 41 carries no adjudicative weight on patent validity or infringement. The court issued no merits ruling, meaning US7763615B2 was neither found invalid nor found not infringed. The patent remains fully enforceable against future generic challengers.
Four defendants were named: RK Pharma, Inc., ARCHIS PHARMA LLC, Apicore US, LLC, and Vgyaan Pharmaceuticals, LLC. The multi-defendant structure suggests plaintiffs targeted entities across the lurbinectedin API and formulation supply chain. No defendant counsel appeared on the public docket before the case was dismissed.
Potentially, if the dismissal was without prejudice. However, the public record does not specify the prejudice qualifier, making this question unresolvable from available documents alone. A second voluntary dismissal against the same defendants under Rule 41 would typically operate as a dismissal with prejudice under the ‘two-dismissal rule,’ which would permanently bar refiling on the same claims.
PatSnap Eureka searches patents and litigation data to answer instantly.